Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 409

Sort by

Sort Order Select

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

A Multi-Center Quality Improvement Intervention to Reduce the Inappropriate Use of Aspirin Among Patients Anticoagulated with Warfarin for Atrial Fibrillation or Venous Thromboembolism

Jordan K Schaefer, MD, Josh Errickson, PhD, Xiaokui Gu, MA, Tina Alexandris-Souphis, RN, Mona A Ali, PharmD, Brian Haymart, RN, MS, Scott Kaatz, DO, MSc, Eva Kline-Rogers, RN, MS, Jay H Kozlowski, MD, Gregory D Krol, Suman L Sood, MD, James B Froehlich, MD MPH, Geoffrey D Barnes, MD MSc

Blood (2019) 134 (Supplement_1): 788.

https://doi.org/10.1182/blood-2019-123067

Published: 2019

Journal Articles

Venous-Thromboembolism in Elderly Patients with Acute Myeloid Leukemia

Radhika Gangaraju, MD, Smita Bhatia, MDMPH, Kelly Kenzik, PhD

Blood (2019) 134 (Supplement_1): 4679.

https://doi.org/10.1182/blood-2019-124464

Published: 2019

Journal Articles

JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm

Melissa Castiglione, BS, Christopher Mazzeo, BS, Ya-Ping Jiang, Juei-Suei Chen, Wei Yin, Richard Lin, Huichun Zhan, MD

Blood (2019) 134 (Supplement_1): 7.

https://doi.org/10.1182/blood-2019-131372

Published: 2019

Journal Articles

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Michelle Janania Martinez, MD, Juan F Garza, MD, Tyler W Snedden, MD, Prathibha Surapaneni, MD, Snegha Ananth, MBBS, Jeremy Rawlings, MD, David J Gregorio, DO, Sushanth Kakarla, MD, Qianqian Liu, PhD, Joel E Michalek, PhD, Adolfo Enrique Diaz, MD

Blood (2019) 134 (Supplement_1): 2204.

https://doi.org/10.1182/blood-2019-129442

Published: 2019

Journal Articles

An Assessment of Race As a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B Cell Lymphoma

Ahmed Toure, BA, Yiyuan Wu, MS, Paul J Christos, Dr.P.H., M.S., Peter Martin, FRCPC, MD MS

Blood (2019) 134 (Supplement_1): 2205.

https://doi.org/10.1182/blood-2019-131567

Published: 2019

Journal Articles

In-Hospital Morbidity and Mortality Among Acute Myeloid Leukemia Patients Admitted for Hematopoeitic Stem Cell Transplants between 2002-2014

Saqib Abbasi, MD, Osama Diab, MD, Ghulam Rehman Mohyuddin, MD, Anurag K. Singh, MD

Blood (2019) 134 (Supplement_1): 2147.

https://doi.org/10.1182/blood-2019-131832

Published: 2019

Journal Articles

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Muhammad Zain Farooq, MD MBBS, Prasanth Lingamaneni, Saira Farid, MD, Muhammad Saad Farooq, MBBS, Ishaan Vohra, MD, Asim Tameez ud din, MD, Ankit Mangla, MBBS,MD

Blood (2019) 134 (Supplement_1): 3465.

https://doi.org/10.1182/blood-2019-132151

Published: 2019

Journal Articles

Impact of Parenteral Iron Therapy on Hemoglobin Normalization: A Retrospective Analysis

Chris LaVallee, M.S, Patrick Cronin, M.A, Isha Bansal, M.S, Jackie Kwong, PhD PharmD, Ralph Boccia, MD

Blood (2019) 134 (Supplement_1): 3445.

https://doi.org/10.1182/blood-2019-125793

Published: 2019

Journal Articles

Inpatient Hospitalization's Associated Cost and Mortality for Myeloma Patients Undergoing Autologous Stem Cell Transplant: A 13-Year Analysis of the National Inpatient Sample

Saqib Abbasi, MD, Brian McClune, DO, Leyla Shune, MD, Suman Kambhampati, MD, Saqib Abbasi, MD

Blood (2019) 134 (Supplement_1): 3431.

https://doi.org/10.1182/blood-2019-131622

Published: 2019

Journal Articles

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Andrew Sochacki, MD, Cosmin Adrian Bejan, PhD, Shilin Zhao, PhD, Travis Spaulding, MD, Shannon Stockton, MD, Alexander Silver, Dixon Dorand, MD PhD, Siwei Zhang, PhD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2959.

https://doi.org/10.1182/blood-2019-121513

Published: 2019

Journal Articles

Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel

Nirmish Shah, David Beenhouwer, Michael S Broder, MD MSHS, Lanetta Bronte-Hall, Laura De Castro, MD MHSc, Sarah N Gibbs, Victor R Gordeuk, MD, Julie Kanter, MD, Elizabeth S Klings, MD, Thokozeni Lipato, MD, Deepa Manwani, MD, Brigid Scullin, Irina Yermilov, Wally R Smith, MD

Blood (2019) 134 (Supplement_1): 415.

https://doi.org/10.1182/blood-2019-121556

Published: 2019

Journal Articles

Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Elizabeth Stenger, MD, Rachel Phelan, MDMPH, Bronwen E. Shaw, MD PhD, Minoo Battiwalla, MD, Stephanie Bo-Subait, MPH, Ruta Brazauskas, PhD, David K. Buchbinder, MD MSHS, Betty K. Hamilton, MD, Shalini Shenoy, MD, Lakshmanan Krishnamurti, MD

Blood (2019) 134 (Supplement_1): 697.

https://doi.org/10.1182/blood-2019-128797

Published: 2019

Journal Articles

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Melissa C Larson, MS, Cristine Allmer, BS, Susan L. Slager, PhD, Thomas M. Habermann, MD, Sunnia T Chen, BS, Hector R Villarraga, MD, Joerg Herrmann, MD, Gita Thanarajasingam, MD, Alessia Castellino, MD, Grzegorz Nowakowski, MD, David J Inwards, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2019) 134 (Supplement_1): 422.

https://doi.org/10.1182/blood-2019-127203

Published: 2019

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Blood (2019) 134 (Supplement_1): 357.

https://doi.org/10.1182/blood-2019-131939

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Abby Statler, PhDMPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3836.

https://doi.org/10.1182/blood-2019-128853

Published: 2019

Journal Articles

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Courtney D. DiNardo, MDMSc, Rebecca Olin, MDMS, Jo Ishizawa, MD PhD, Hiroyuki Sumi, PhD, Jingdong Xie, PhD, Kazunobu Kato, MD PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3932.

https://doi.org/10.1182/blood-2019-122241

Published: 2019

Journal Articles

Risk Factors and Trends for Incidence of Acute Coronary Syndrome after Hematopoietic Stem Cell Transplant - a 15-Year Experience with National Inpatient Sample

Jasdeep Singh Sidhu, MBBS, Jeevanjot Kaur Virk, MBBS, Shivani Handa, MBBS, Amrendra Mandal, Sridevi Rajeeve, MD

Blood (2019) 134 (Supplement_1): 4564.

https://doi.org/10.1182/blood-2019-127487

Published: 2019

Journal Articles

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Sunnia T Chen, BS, Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Cristine Allmer, BS, Dennis P. Robinson, Grzegorz Nowakowski, MD, Thomas M. Habermann, MD, Susan L Slager, PhD, Carrie A. Thompson, MD, James R. Cerhan, MD PhD

Blood (2019) 134 (Supplement_1): 5215.

https://doi.org/10.1182/blood-2019-128775

Published: 2019

NARROW

AL patients don’t dare go without dara

A Multi-Center Quality Improvement Intervention to Reduce the Inappropriate Use of Aspirin Among Patients Anticoagulated with Warfarin for Atrial Fibrillation or Venous Thromboembolism

Venous-Thromboembolism in Elderly Patients with Acute Myeloid Leukemia

JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

An Assessment of Race As a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B Cell Lymphoma

In-Hospital Morbidity and Mortality Among Acute Myeloid Leukemia Patients Admitted for Hematopoeitic Stem Cell Transplants between 2002-2014

A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Impact of Parenteral Iron Therapy on Hemoglobin Normalization: A Retrospective Analysis

Inpatient Hospitalization's Associated Cost and Mortality for Myeloma Patients Undergoing Autologous Stem Cell Transplant: A 13-Year Analysis of the National Inpatient Sample

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel

Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Risk Factors and Trends for Incidence of Acute Coronary Syndrome after Hematopoietic Stem Cell Transplant - a 15-Year Experience with National Inpatient Sample

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only